Journal of Stem Cell Research & Therapy

Mismatch of Oncogene Occurrence and Cancer Incidence in Early Life

Giorgio Linares^* Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, California, USA
^*Correspondence: Giorgio Linares, Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, California, USA, Email:

Received: 06-May-2024, Manuscript No. JSCRT-24-26193; Editor assigned: 08-May-2024, Pre QC No. JSCRT-24-26193 (PQ); Reviewed: 22-May-2024, QC No. JSCRT-24-26193; Revised: 29-May-2024, Manuscript No. JSCRT-24-26193 (R); Published: 06-Jun-2024, DOI: 10.35248/2157-7633.24.14.638

Description

Cancer, a multifaceted and formidable disease, has been a significant focus of medical research for decades. Its origins are often traced back to genetic mutations, particularly in oncogenes, which are genes that, when mutated or expressed at high levels, can transform a normal cell into a cancerous one. Interestingly, despite the presence of oncogene mutations in early life, the incidence of cancer in young individuals remains relatively low compared to adults. This phenomenon, known as the "mismatch of oncogene occurrence and cancer incidence," raises an important questions about the underlying mechanisms that protect young organisms from developing cancer and highlights the complex exchange between genetic mutations and cancer development.

The role of oncogenes

Oncogenes are critical components in the regulation of cell growth and differentiation. When these genes are mutated or dysregulated, they can lead to uncontrolled cell proliferation, a sign of cancer. In early life, particularly during embryonic development and childhood, cells undergo rapid division and differentiation. This period of heightened cellular activity increases the likelihood of mutations, including those in oncogenes [1-3].

Oncogene occurrence in early life

Studies have shown that oncogenic mutations can occur surprisingly early in life. Some mutations are even detected in embryonic development. For instance, the RET gene, commonly associated with multiple endocrine neoplasia type 2, can harbor mutations that arise during embryogenesis. Similarly, mutations in the ALK gene, which are implicated in neuroblastoma, a common pediatric cancer, can be present from birth [4].

Despite these early occurrences of oncogenic mutations, the actual incidence of cancer in children remains significantly lower than in adults [5]. This discrepancy suggests that the presence of oncogene mutations alone is not sufficient to cause cancer, particularly in the early stages of life. Instead, additional factors and mechanisms must be at play to suppress or delay cancer development.

Protective mechanisms in early life

Several protective mechanisms are hypothesized to contribute to the lower incidence of cancer in young individuals, despite the presence of oncogene mutations.

Enhanced DNA repair mechanisms: Young organisms possess highly efficient DNA repair mechanisms that can correct mutations before they result in malignant transformations. These repair systems, including nucleotide excision repair and mismatch repair pathways, are particularly active during early development, ensuring genomic integrity during rapid cell division [6].

Apoptosis and senescence: Cells with significant genetic damage can undergo programmed cell death (apoptosis) or enter a state of permanent growth arrest (senescence). These processes act as critical barriers to cancer development by eliminating or halting the proliferation of potentially malignant cells. In early life, the apoptotic response is strong, effectively preventing the accumulation of oncogene-driven cellular populations.

Immune surveillance: The immune system plays an important role in identifying and eliminating abnormal cells. In young individuals, the immune system is highly active and can effectively recognize and destroy cells harboring oncogenic mutations. This immune surveillance acts as a formidable defense against the early onset of cancer [7].

Microenvironmental factors: The cellular microenvironment in early life may also contribute to the suppression of cancer. Factors such as growth signals, extracellular matrix components, and interactions with surrounding cells can influence the behavior of potentially cancerous cells. In a developing organism, these microenvironmental conditions may be less conducive to the establishment and growth of tumors [8,9].

Cancer incidence and aging

As individuals age, the balance between oncogene occurrence and cancer incidence shifts. The cumulative effect of genetic mutations, decreased efficiency of DNA repair mechanisms, reduced apoptotic response, and a decline in immune surveillance contribute to the increased cancer incidence observed in adults. Furthermore, the aging microenvironment may become more permissive to tumor development, providing a fertile ground for oncogene-driven cells to proliferate and form malignancies [10].

Conclusion

The mismatch of oncogene occurrence and cancer incidence in early life establishes the complexity of cancer development. While oncogene mutations are present from a young age, multiple protective mechanisms act in concert to prevent the early onset of cancer. Understanding these protective factors offers valuable insights into cancer biology and highlights potential methods for therapeutic intervention.

Research into the exchange between genetic mutations and protective mechanisms continues to be of importance. By resolving the complex network of factors that safeguard young organisms from cancer, scientists can develop strategies to enhance these defenses, potentially leading to novel approaches in cancer prevention and treatment across all age groups.

References

1. Szyf M. The early life environment and the epigenome. Biochim Biophys Acta. 2009;1790(9):878-885.

   [Crossref] [Google Scholar] [PubMed]

2. Bolande RP. Spontaneous regression and cytodifferentiation of cancer in early life: The oncogenic grace period. Surv Synth Pathol Res. 1985;4(4):296-311.

   [Crossref] [Google Scholar] [PubMed]

3. DeGregori J. Challenging the axiom: Does the occurrence of oncogenic mutations truly limit cancer development with age?. Oncogene. 2013;32(15):1869-1875.

   [Crossref] [Google Scholar] [PubMed]

4. Podlutsky A, Valcarcel-Ares MN, Yancey K, Podlutskaya V, Nagykaldi E, Gautam T, et al. The GH/IGF-1 axis in a critical period early in life determines cellular DNA repair capacity by altering transcriptional regulation of DNA repair-related genes: implications for the developmental origins of cancer. Geroscience. 2017;39:147-160.

   [Crossref] [Google Scholar] [PubMed]

5. Filbin M, Monje M. Developmental origins and emerging therapeutic opportunities for childhood cancer. Nat Med. 2019;25(3):367-376.

   [Crossref] [Google Scholar] [PubMed]

6. Meyn RE, Munshi A, Haymach JV, Milas L, Ang KK. Receptor signaling as a regulatory mechanism of DNA repair. Radiother Oncol. 2009;92(3):316-322.

   [Crossref] [Google Scholar] [PubMed]

7. Schmitt CA. Senescence, apoptosis and therapy-cutting the lifelines of cancer. Nat Rev Cancer. 2003;3(4):286-295.

   [Crossref] [Google Scholar] [PubMed]

8. Kim R. Cancer immunoediting: From immune surveillance to immune escape. Immunology. 2007:9-27.

   [Crossref] [Google Scholar] [PubMed]

9. Banfi A, von Degenfeld G, Blau HM. Critical role of microenvironmental factors in angiogenesis. Curr Atheroscler Rep. 2005;7(3):227-234.

   [Crossref] [Google Scholar] [PubMed]

10. Durand RE. The influence of microenvironmental factors during cancer therapy. In Vivo. 1994;8(5):691-702.

    [Google Scholar] [PubMed]